Cerebral meningioma
Meaning of cerebral meningioma: For the purposes of this Statement of Principles, cerebral meningioma means a primary benign or intermediate grade tumour of the cerebral meninges. (3) While cerebral meningioma attracts ICD-10-AM code D32.0 or D32.9, in applying this Statement of Principles the meaning of cerebral meningioma is that given in subsection (2). (4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Reasonable Hypothesis (RH) — Statement of Principles No. 1 of 2018
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting cerebral meningioma or death from cerebral meningioma with the circumstances of a person's relevant service:
- (1)having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the brain at least five years before the clinical onset of cerebral meningioma;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
- (2)being overweight or obese for at least five years within the 20 years before the clinical onset of cerebral meningioma;
Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
- (3)being in the second or third trimester of pregnancy, or within the 30 days postpartum, at the time of the clinical onset of cerebral meningioma;
- (4)being treated with a drug as specified within the ten years before the clinical onset of cerebral meningioma;
Note: being treated with a drug as specified is defined in the Schedule 1 - Dictionary.
- (5)using hormone replacement therapy for a continuous period of at least six months before the clinical onset of cerebral meningioma, and where the use of hormone replacement therapy has ceased, the clinical onset of cerebral meningioma has occurred within ten years of cessation;
Note: hormone replacement therapy is defined in the Schedule 1 - Dictionary.
- (6)being in the second or third trimester of pregnancy, or within the 30 days postpartum, at the time of the clinical worsening of cerebral meningioma;
- (7)being treated with a drug as specified within the ten years before the clinical worsening of cerebral meningioma;
Note: being treated with a drug as specified is defined in the Schedule 1 - Dictionary.
- (8)inability to obtain appropriate clinical management for cerebral meningioma;
Aggravation-only factors: the factors in subsections 9(6) to 9(8) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.
Balance of Probabilities (BoP) — Statement of Principles No. 2 of 2018
7 factors
At least one of the following factors must exist before it can be said that, on the balance of probabilities, cerebral meningioma or death from cerebral meningioma is connected with the circumstances of a person's relevant service:
- (1)having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the brain at least ten years before the clinical onset of cerebral meningioma;
Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
- (2)being obese for at least ten years within the 20 years before the clinical onset of cerebral meningioma;
Note: being obese is defined in the Schedule 1 - Dictionary.
- (3)being in the second or third trimester of pregnancy, or within the 30 days postpartum, at the time of the clinical onset of cerebral meningioma;
- (4)being treated daily with cyproterone acetate at a dose rate of at least 15 milligrams per day for a continuous period of at least one year, within the ten years before the clinical onset of cerebral meningioma;
- (5)being in the second or third trimester of pregnancy, or within the 30 days postpartum, at the time of the clinical worsening of cerebral meningioma;
- (6)being treated daily with cyproterone acetate at a dose rate of at least 15 milligrams per day for a continuous period of at least one year, within the ten years before the clinical worsening of cerebral meningioma;
- (7)inability to obtain appropriate clinical management for cerebral meningioma;
Aggravation-only factors: the factors in subsections 9(5) to 9(7) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.
